Hao Pan

Hao Pan

Auto-generated profile, based on publicly available information

Hao Pan

Department of Orthopaedic Surgery Department of Wound Healing The First Affiliated Hospital of Wenzhou Medical University Wenzhou Zhejiang China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2024 in Science Advances
Verified
Journal Article
Open access
YWYuxuan Wei
Yuxuan Wei
HPHao Pan
Hao Pan
JYJianqiu Yang
Jianqiu Yang
CZCan jun Zeng
Can jun Zeng
WWWenbing Wan Wenbing Wan
Wenbing Wan Wenbing Wan
SCSHIXUAN CHEN
SHIXUAN CHEN
Reconstructing extensive cranial defects represents a persistent clinical challenge. Here, we reported a hybrid three-dimensional (3D) printed scaffold with modification of QK peptide and KP peptide for effectively promoting endogenous cranial bone regeneration. The hybrid 3D printed scaffold consists of vertically aligned cryogel fibers that guide and promote cell penetration into the defect area in the early stages of bone repair. Then, the conjugated QK peptide and KP peptide further regulate the function of the recruited cells to promote vascularization and osteogenic differentiation in the defect area. The regenerated bone volume and surface coverage of the dual peptide-modified hybrid scaffold were significantly higher than the positive control group. In addition, the dual peptide-modified hybrid scaffold demonstrated sustained enhancement of bone regeneration and avoidance of bone resorption compared to the collagen sponge group. We expect that the design of dual peptide-modified hybrid scaffold will provide a promising strategy for bone regeneration.

5 August 2026 in Advanced Materials
Verified
Journal Article
Open access
PDF file
HPHao Pan
Hao Pan
HZHaoze Zhu
Haoze Zhu
SHSiman Huang
Siman Huang
LCLikai Chen
Likai Chen
CLCailong Liu
Cailong Liu
JXJian Xiao
Jian Xiao
Osteoarthritis (OA), a global leading cause of chronic pain and disability, lacks disease‐modifying osteoarthritis drugs (DMOADs) targeting its core pathogenesis. scRNA‐seq of human OA cartilage showed marked depletion of a high‐arginine‐metabolism chondrocyte subpopulation driving cartilage degeneration, with its key upstream regulator FGF21, significantly downregulated in OA cartilage. Mechanistically, FGF21 rescues IL‐1β‐induced chondrocyte dysfunction via ASS1/ASL ‐mediated arginine biosynthesis, an effect abrogated by ASS1 knockdown, confirming the FGF21‐arginine pathway's role and FGF21 as a therapeutic target. Guided by this mechanism, we engineered a hydrogel‐based bioinspired metabo‐reprogramming niche remodeling system (MetaRemod) to achieve precise and efficient delivery of FGF21 to OA chondrocytes. In a mouse OA model, MetaRemod effectively halted OA progression by sustaining targeted delivery of bioactive FGF21, restoring chondrocyte arginine metabolism, preserving cartilage structure and joint space, restoring subchondral bone integrity, and mitigating synovitis. Critically, scRNA‐seq of treated cartilage confirmed the restoration of the depleted “high‐arginine‐metabolism” chondrocyte subpopulation, directly validating that MetaRemod reverses OA's core metabolic defect. This study establishes the FGF21‐arginine metabolic axis as a key therapeutic target for OA and validates MetaRemod as a promising strategy that synergizes targeted FGF21 delivery and metabolic reprogramming, laying a solid foundation for the clinical translation of metabolic reprogramming‐based DMOADs.

20 February 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
HPHao Pan
Hao Pan
MZMin Zhang
Min Zhang
LCLikai Chen
Likai Chen
HZHaoze Zhu
Haoze Zhu
SHSiman Huang
Siman Huang
CLCailong Liu
Cailong Liu
The management of critical-sized craniomaxillofacial bone defects remains a formidable clinical challenge due to the concomitant issues of prolonged inflammation, inadequate vascularization, and insufficient endogenous osteogenesis. Herein, a novel cell-free bone regeneration strategy is reported based on biomimetic apoptotic nanovesicles (Apo-NVs) derived from apoptotic T-lymphocytes membrane. The Apo-NVs, which mimic the "find-me" and "eat-me" signals of natural apoptotic cells, are engineered into a gelatin methacryloyl (GelMA) hydrogel for sustained localized delivery. In vitro, the Apo-NVs demonstrate superior immunomodulatory efficacy by promoting the repolarization of pro-inflammatory M1 macrophages towards a pro-healing M2 phenotype. Concurrently, they directly enhance the osteogenic differentiation of bone marrow-derived mesenchymal stem cells (BMSCs) and potently stimulate human umbilical vein endothelial cells (HUVECs) proliferation, migration, and tube formation. In vivo, the GelMA-Apo-NVs significantly augments bone regeneration and vascularization compared to GelMA and GelMA-NVs groups, as validated by micro-computed tomography and histological analyses. Mechanistic unraveling through transcriptomic profiling reveals that the regenerative function of Apo-NVs is orchestrated through the activation of Wnt/β-catenin signaling pathway. This activation not only directly drives osteogenic gene expression but also upregulates vegfa, thereby coupling angiogenesis with osteogenesis, while simultaneously inhibiting the NF-κB pathway to inhibit inflammation. This study pioneers a versatile apoptotic vesicle-based platform that harmonizes the immune-osteogenic-vascular triad, presenting a potent and promising therapeutic paradigm for regenerative medicine.